AD-209-1B

AD-209-1B is a specific dose formulation of AD-209, an investigational triple fixed-dose combination (FDC) therapy developed by Addpharma Inc. for the treatment of essential hypertension. It contains three active ingredients: amlodipine (a calcium channel blocker), chlorthalidone (a thiazide-like diuretic), and telmisartan (an angiotensin II receptor blocker). This combination targets multiple pathways of blood pressure regulation, including the renin-angiotensin-aldosterone system, calcium-mediated vascular contraction, and renal sodium reabsorption. It is classified as an incrementally modified drug (IMD) in South Korea and is administered orally as a film-coated tablet. The drug aims to provide superior blood pressure control compared to dual therapies by combining complementary mechanisms of action.

Other names

amlodipine + chlorthalidone + telmisartan